Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative
RNA-based therapeutics, will host a webcast and conference call for the
Duchenne muscular dystrophy (DMD) community on Tuesday, May 13, 2014,
beginning at 11:00 a.m. EDT (8:00 a.m. PDT / 5:00 p.m. CEST).
Chris Garabedian, president and chief executive officer, and Edward
Kaye, M.D., chief medical officer, will provide information and answer
questions about Sarepta's DMD development program, including upcoming
clinical trials. Sarepta has invited DMD community representatives from
leading patient advocacy groups to participate in the question and
answer portion of the webcast.
To access the webcast, visit the events and presentations section of
Sarepta's website at www.sarepta.com/events
and follow the link for the webcast under "Upcoming Events." Please
connect several minutes prior to the start of the broadcast to ensure
adequate time for any software download that may be necessary.
To access only the audio portion, dial in to 1-888-895-5479 (U.S. toll
free) for U.S. domestic callers or 1-847-619-6250 for international
callers. The passcode for the call is 37195657. Please specify to the
operator that you would like to join the "Sarepta DMD Development
Program Update."
Following the event, the webcast will be archived in the events and
presentations section of Sarepta's website for 90 days.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based
therapeutics to improve and save the lives of people affected by serious
and life-threatening rare and infectious diseases. The company's diverse
pipeline includes its lead program eteplirsen, for Duchenne muscular
dystrophy, as well as potential treatments for some of the world's most
lethal infectious diseases. Sarepta aims to build a leading, independent
biotech company dedicated to translating its RNA-based science into
transformational therapeutics for patients who face significant unmet
medical needs. For more information, please visit us at www.sarepta.com.
Copyright Business Wire 2014